Background Urothelial carcinoma (UC) is a common malignancy with a high mortality rate
when metastatic. Traditionally, systemic therapy consisted in platinum-based regimens as …

Combination platinum-based chemotherapy has been the standard of care for several
decades in first-line treatment of advanced urothelial carcinoma (UC) patients. UC is often …

Immunotherapy represents a new hope for patients with advanced urothelial carcinoma
(UC). However, to date, only one of two randomized studies showed a clear survival …

Abstract Purpose of Review Until recently, effective treatment options for patients with
advanced urothelial carcinoma were limited to platinum-based chemotherapy. In the post …

Immunotherapy is changing the landscape of cancer therapeutics. Although this has been
most pronounced in the management of patients with advanced melanoma, monoclonal …

Opinion statement Checkpoint inhibitors have monumentally transformed the treatment of
metastatic urothelial carcinoma. While the efficacy and safety of the different agents are …

Opinion statement Immune checkpoint inhibitors have importantly improved the outcome of
patients with urothelial carcinoma. Different immune checkpoint inhibitors are currently …

Advancements in the understanding of tumor immunology in urothelial carcinoma (UC) have
led to US Food and Drug Administration (FDA) approval of five novel anti-programmed cell …

Systemic therapy for metastatic urothelial carcinoma has seen minimal progress and no new
approved therapies in the past 20 years. However, with the approval of the checkpoint …

Background Pembrolizumab and atezolizumab have recently been approved for the first-line
treatment of patients with advanced urothelial carcinoma (aUC) who are not eligible for …